Palatin's stock rockets after FDA OK to market sexual desire disorder treatment

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 97%

Sverige Nyheter Nyheter

Sverige Senaste nytt,Sverige Rubriker

Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG...

Shares of Palatin Technologies Inc. PTN, +4.69% rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on

, +4.06% treatment for hypoactive sexual desire disorder triggered a $60 million milestone payment. Trading volume was over 2.9 million shares, making Palatin's stock the most actively traded ahead of the open. The FDA granted marketing approval for 's stock surged 8.1% ahead of the open. The company expects to receive the milestone payment in July. Based on the license agreement with

 

Tack för din kommentar. Din kommentar kommer att publiceras efter att ha granskats.

BringeReprobate

Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer:

 /  🏆 3. in SE

Sverige Senaste nytt, Sverige Rubriker

Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.

Believing all this talk about a stock market bubble can land you in real troubleS&P 500 gains aren’t large enough to prove the market is overheated, writes Mark Hulbert.
Källa: MarketWatch - 🏆 3. / 97 Läs mer »